The latest book, "Pox: Genius, Madness and the Mysteries of Syphilis ... Dr Redlich said that another condition, giant cell arteritis, an autoimmune disease which causes inflammation of the arteries, ...

In this Healio Video Perspective, Andrew G. Lee, MD, discusses whether temporal artery ultrasound can be used in place of ...

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for ...

The FDA has approved Rinvoq (upadacitinib), a Janus kinase inhibitor, for the treatment of adults with giant cell arteritis.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.